» Articles » PMID: 20076847

Polymorphisms in Platelet Glycoproteins Ia and IIIa Are Associated with Arterial Thrombosis and Carotid Atherosclerosis in Type 2 Diabetes

Overview
Journal Thromb Haemost
Publisher Thieme
Date 2010 Jan 16
PMID 20076847
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

To determine the genotype distributions of the polymorphisms in platelet glycoproteins (GP) Ib-alpha, Ia/IIa and IIb/IIIa and their association with clinical arterial thrombosis and preclinical carotid atherosclerosis in type 2 diabetes we studied 229 patients with type 2 diabetes and 229 controls matched by age, gender and ethnicity. Biochemical and haemostasis analyses were performed. The GP Ib-alpha VNTR, GP Ia 807 C/T and GP IIIa Pl(A) polymorphisms were determined by PCR. Thrombotic events were registered and carotid atherosclerosis was evaluated by ultrasound examination. A total of 107 patients had clinical atherothrombosis (CA), 65 subclinical atherosclerosis (SA), and 57 had no evidence of atherosclerosis (NA). There were no differences in allele frequencies and the genotype distribution of platelet GP polymorphisms between diabetic patients and controls. The VNTR Ib-alpha polymorphism was not associated with CA. We found a significant association between CA and the 807T (odds ratio [OR]: 2.86, confidence interval [CI]: 1.65-4.93; p<0.001) and PlA2 (OR: 2.03, CI: 1.13-3.65; p=0.03) alleles (in GP Ia and GP IIIa, respectively) in comparison to SA and NA group. Diabetic patients with the coexistence of the 807T and PlA2 alleles presented the highest risk of CA (OR: 3.59, CI: 1.64-7.8; p<0.001). The coexistence of both 807T and PlA2 alleles was also associated with the presence of SA (OR: 9.00, CI: 1.10-73.42; p=0.04). In conclusion, the 807T allele of GP Ia and the PlA2 allele of GP IIIa, and specially its combination, may confer an additional risk for development of carotid atherosclerosis and arterial thrombosis in type 2 diabetes.

Citing Articles

The Perspectives of Platelet Proteomics in Health and Disease.

Chaudhary P, Upadhayaya S, Kim S, Kim S Biomedicines. 2024; 12(3).

PMID: 38540198 PMC: 10968484. DOI: 10.3390/biomedicines12030585.


The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis.

Floyd C, Mustafa A, Ferro A PLoS One. 2014; 9(7):e101518.

PMID: 24988220 PMC: 4079717. DOI: 10.1371/journal.pone.0101518.


The a1/a2 polymorphism of the glycoprotein IIIa gene and myocardial infarction in Caucasians with type 2 diabetes.

Nikolajevic-Starcevic J, Petrovic D Mol Biol Rep. 2012; 40(3):2077-81.

PMID: 23184042 DOI: 10.1007/s11033-012-2265-9.


Anti-platelet therapy: glycoprotein IIb-IIIa antagonists.

Schneider D Br J Clin Pharmacol. 2011; 72(4):672-82.

PMID: 21906121 PMC: 3195742. DOI: 10.1111/j.1365-2125.2010.03879.x.


Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development.

Williams M, Weiss E, Sabatine M, Simon D, Bahou W, Becker L Arterioscler Thromb Vasc Biol. 2010; 30(12):2372-84.

PMID: 21084706 PMC: 4118751. DOI: 10.1161/ATVBAHA.110.218131.